HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sandrin C Bergheanu Selected Research

ST Elevation Myocardial Infarction

5/2011The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents.
10/2009Post-intervention IVUS is not predictive for very late in-stent thrombosis in drug-eluting stents.
8/2009In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
3/2009Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention.
4/2008Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sandrin C Bergheanu Research Topics

Disease

6Myocardial Infarction
01/2011 - 03/2009
5Thrombosis (Thrombus)
08/2011 - 04/2008
5ST Elevation Myocardial Infarction
05/2011 - 04/2008
2Infarction (Infarctions)
08/2009 - 03/2009
1Mitochondrial Diseases (Mitochondrial Disease)
01/2021
1Atherosclerosis
01/2018
1Cardiovascular Diseases (Cardiovascular Disease)
01/2018
1Inflammation (Inflammations)
05/2011
1Neointima
11/2009
1Sudden Death
10/2009
1Heart Failure
08/2009
1Necrosis
03/2009
1Coronary Artery Disease (Coronary Atherosclerosis)
09/2008

Drug/Important Bio-Agent (IBA)

3Sirolimus (Rapamycin)FDA Link
05/2011 - 04/2008
3MetalsIBA
05/2010 - 04/2008
2Rosuvastatin Calcium (Crestor)FDA Link
01/2018 - 09/2008
2Atorvastatin (Lipitor)FDA Link
01/2018 - 09/2008
1Huntingtin ProteinIBA
01/2021
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2018
1Troponin IIBA
01/2018
1PolymersIBA
08/2011
1poly(3- hydroxybutyrate)- co- (3- hydroxyvalerate)IBA
08/2011
1N,N-dimethylarginine (asymmetric dimethylarginine)IBA
01/2011
1Abciximab (ReoPro)FDA Link
08/2009
1Plasminogen Activators (Plasminogen Activator)IBA
05/2009
1Troponin T (Troponin T1)IBA
03/2009
1Biomarkers (Surrogate Marker)IBA
03/2009
1Indicators and Reagents (Reagents)IBA
03/2009
1Creatine Kinase (Creatine Phosphokinase)IBA
03/2009
1LipidsIBA
09/2008

Therapy/Procedure

6Stents
08/2011 - 04/2008
3Percutaneous Coronary Intervention
08/2009 - 04/2008
2Drug-Eluting Stents
05/2010 - 10/2009
1Therapeutics
01/2018